ArticleJournal of translational medicine2026
Integrative transcriptomic and experimental analysis identifies GREM1 as a pro-metastatic mediator in lung adenocarcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe TGF-β signaling pathway can effectively activate epithelial-mesenchymal transition and glycolysis, thereby promoting tumor metastasis and drug resistance. Bioinformatics analyses have indicated that GREM1 may facilitate tumor progression and metastasis. However, the mechanism by which GREM1 promotes metastasis in lung adenocarcinoma remains largely unknown.
methodsWe applied pathway-focused integrative clustering to characterize molecular subgroups demonstrating differential activation of EMT, glycolysis and TGF-β pathways, subsequently developing different prognosis subtypes. Comprehensive functional investigations encompassing wound healing assays, migration, invasion, apoptosis evaluations and metastasis models were performed to elucidate GREM1's role in cancer progression. Mechanistic explorations through WB, co-IP techniques and virtual knockout revealed critical downstream effectors and signaling networks modulated by GREM1 activity.
resultsIntegrative clustering identified two LUAD subtypes with distinct oncogenic pathways activity and different survival outcomes. GREM1 was prioritized as a CS2-associated core gene and was associated with poor prognosis. Functional assays showed that GREM1 enhanced LUAD cell migration, invasion, glucose uptake, and lung metastatic colonization, while suppressing apoptosis. Mechanistically, GREM1 interacts with BMP2 and induces epithelial-mesenchymal transition and glycolysis via the TGF-β signaling pathway, thereby promoting LUAD progression and metastasis.
conclusionsGREM1 emerges as both a metastasis driver and therapeutic target, offering opportunities for biomarker-guided precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.